How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Imaging In Clinical Trials Market
- By Imaging Modality: Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography (PET), Ultrasound Imaging, X-ray Imaging
- By Application Area: Oncology, Cardiology, Neurology, Orthopedics, Inflammatory Diseases
- By End User: Pharmaceutical Companies, Contract Research Organizations (CROs), Academic and Research Institutes, Biotechnology Companies, Medical Imaging Service Providers
- By Clinical Trial Phase: Phase I, Phase II, Phase III, Phase IV
- By Imaging Technique: Functional Imaging, Anatomical Imaging, Molecular Imaging, Hybrid Imaging
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Magnetic Resonance Imaging (MRI) leads By Imaging Modality at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 303 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.182 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.190 →
Full report · locked preview
Everything inside the Imaging In Clinical Trials Market report
A complete, evidence-based study - 12 chapters and 127 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Imaging Modality 5
Application Area 5
End User 5
Clinical Trial Phase 4
Imaging Technique 4
Companies profiled
ICON plc
Parexel International Corporation
IQVIA Holdings Inc.
PPD
Inc. (Thermo Fisher Scientific)
Labcorp Drug Development (Covance)
Syneos Health Inc.
Medpace Holdings Inc.
Charles River Laboratories International Inc.
PRA Health Sciences Inc.
Novotech Pty Ltd
Worldwide Clinical Trials Inc.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →ICON plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Parexel International Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →IQVIA Holdings Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →PPD
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Inc. (Thermo Fisher Scientific)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Labcorp Drug Development (Covance)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Syneos Health Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Medpace Holdings Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Charles River Laboratories International Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →PRA Health Sciences Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Novotech Pty Ltd
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Worldwide Clinical Trials Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Clinipace Worldwide
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →BioClinica Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Invicro LLC
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Imaging Endpoints LLC
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$826.5M by 2033 · 6.6% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Magnetic Resonance Imaging (MRI)53.4
- Computed Tomography (CT)15.6
- Positron Emission Tomography (PET)12.4
- Ultrasound Imaging7.0
- X-ray Imaging11.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$163.6M → $272.1M · 6.6%
Europe$114.0M → $180.3M · 5.9%
Asia Pacific$104.1M → $182.5M · 7.3%
Latin America$64.5M → $100.6M · 5.7%
Middle East and Africa$49.6M → $88.3M · 7.5%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.552026
6.562027
6.582028
6.582029
6.602030
6.622031
6.632032
6.642033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- ICON plc21.1
- Parexel International Corporation21.7
- IQVIA Holdings Inc.5.9
- PPD9.0
- Inc. (Thermo Fisher Scientific)6.3
- Labcorp Drug Development (Covance)8.0
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Imaging Modality26.0%
Application Area13.8%
End User24.6%
Clinical Trial Phase12.9%
Imaging Technique22.8%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.0
- Europe21.9
- Asia Pacific22.2
- Latin America12.2
- Middle East and Africa10.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| ICON plc | 85 | 89 | 85 | 88 | 99 | 77 | 87 |
| Parexel International Corporation | 85 | 93 | 71 | 77 | 78 | 81 | 81 |
| IQVIA Holdings Inc. | 80 | 79 | 84 | 85 | 68 | 80 | 79 |
| PPD | 74 | 68 | 65 | 73 | 71 | 64 | 69 |
| Inc. (Thermo Fisher Scientific) | 66 | 67 | 53 | 74 | 55 | 74 | 65 |
| Labcorp Drug Development (Covance) | 54 | 52 | 67 | 51 | 48 | 52 | 54 |
| Syneos Health Inc. | 44 | 56 | 41 | 61 | 63 | 65 | 55 |
| Medpace Holdings Inc. | 41 | 44 | 47 | 58 | 58 | 59 | 51 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- ICON plc
- Parexel International Corporation
- IQVIA Holdings Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| ICON plc | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Parexel International Corporation | ◐ | ✓ | ◐ | ◐ | ✓ | ◐ |
| IQVIA Holdings Inc. | ✓ | ✓ | ◐ | ✓ | ◐ | ◐ |
| PPD | ◐ | ◐ | ◐ | ◐ | − | ◐ |
| Inc. (Thermo Fisher Scientific) | ✓ | − | − | ◐ | − | ◐ |
| Labcorp Drug Development (Covance) | − | − | ◐ | − | ◐ | ◐ |
| Syneos Health Inc. | − | ◐ | − | − | ◐ | ◐ |
| Medpace Holdings Inc. | − | ◐ | ◐ | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1ICON plc87
2Parexel International Corporation81
3IQVIA Holdings Inc.79
4PPD69
5Inc. (Thermo Fisher Scientific)65
6Syneos Health Inc.55
7Labcorp Drug Development (Covance)54
8Medpace Holdings Inc.51
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
ICON plcParexel International CorporationIQVIA Holdings Inc.
Challenger1
Strong scale, closing on the leaders.
PPD
Contender1
Focused players with pockets of strength.
Inc. (Thermo Fisher Scientific)
Niche3
Specialists in a single segment or region.
Labcorp Drug Development (Covance)Syneos Health Inc.Medpace Holdings Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Imaging Modality in North America, then scale across Imaging In Clinical Trials Market — a $416M beachhead inside a $6.51B market.
Beachhead (SOM)$416Mobtainable near-term
Serviceable (SAM)$2.32Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Magnetic Resonance Imaging (MRI)
Best fit — highest urgency & budget in Imaging Modality.
Economic buyer81 fit
Computed Tomography (CT)
Strong fit — clear ROI and a fast path to value.
End user69 fit
Positron Emission Tomography (PET)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Imaging Modality in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application Area & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel28%
Digital / self-serve21%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Imaging Modality leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Imaging In Clinical Trials Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified22%
Evaluation13%
Closed-won7%
$16.3KCAC
$87KLTV
5.3:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Imaging In Clinical Trials Market is a high-growth opportunity — $5.45B by 2033, compounding at 10.0%.
TAM · 2025$2.54Btoday
TAM · 2033$5.45Bforecast
CAGR10.0%2027–2033
Cumulative$34.5Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.45BTotal addressable market
SAM$1.88BServiceable available market
SOM$344MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.0% CAGR
Demand compounds through 2033, outpacing GDP across Imaging Modality.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Imaging Modality moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.45BLarge & growingTAM by 2033 at 10.0% CAGR
$1.88BServiceable nowreachable with today’s model
$344MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.25BBear6.5% CAGR
$5.45BBase10.0% CAGR
$6.97BBull13.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application Area optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Imaging In Clinical Trials Market — a $10.3B market by 2033. Plan: grow share from 10.4% to 17.3%.
Market size · 2033$10.3Btotal addressable
Market CAGR10.0%2027–2033
Target share17.3%from 10.4% today
Revenue ambition$1.79Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.4% | 17.3% | On track |
| Revenue | $1.10B | $1.79B | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 31.9% | 42.3% | On track |
| Customer retention | 86.2% | 94.0% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Imaging Modality
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application Area capability
A defensible second engine — invest in Application Area to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Imaging Modality share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application Area
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $242M capacity & capability investment
- Greenlight bolt-on M&A in Application Area
- Authorise North America expansion plan
- Fund R&D program for Imaging Modality leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeBehind
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Imaging In Clinical Trials Market conversation — a $3.67B market you can size, segment and defend in minutes.
Market size · 2033$3.67Btotal opportunity
Growth10.3%CAGR to 2033
Addressable buyers1,473+accounts in scope
Typical ROI4.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Imaging Modality
Goal Grow share in Imaging Modality
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.4×return on cost, year one
< 4 mopayback period
$96K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
ICON plcParexel International CorporationIQVIA Holdings Inc.PPDInc. (Thermo Fisher Scientific)Labcorp Drug Development (Covance)Syneos Health Inc.Medpace Holdings Inc.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Imaging In Clinical Trials Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Imaging In Clinical Trials Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Imaging Goniometers Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportImaging Flow Cytometer Equipment Market
Market size, share, segmentation and regional forecast.
$309M market · 2025 base year
View reportBenchtop Ion Meters Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportLaboratory Ion Meters Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportImaging Energy Filter (IEF) Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportImaging Cytometer Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportImaging Biomarker Market
Market size, share, segmentation and regional forecast.
$302M market · 2025 base year
View reportLaboratory Sodium Ion Meters Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportLaboratory Calcium Ion Meters Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportLaboratory Ammonium Ion Meters Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportImage Particle Analyzers Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportImage Guide Surgical Navigation System Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.